The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
Richard E Kast,1 Nicolas Skuli,2 Samuel Cos,3 Georg Karpel-Massler,4 Yusuke Shiozawa,5 Ran Goshen,6 Marc-Eric Halatsch4 1IIAIGC Study Center, Burlington, VT, USA; 2INSERM, Centre de Recherches en Cancérologie de Toulouse – CRCT, UMR1037 Inserm/Université Toulouse III...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4e6e679f64db42edab80fb791718a624 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4e6e679f64db42edab80fb791718a624 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4e6e679f64db42edab80fb791718a6242021-12-02T04:17:35ZThe ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy1179-1314https://doaj.org/article/4e6e679f64db42edab80fb791718a6242017-07-01T00:00:00Zhttps://www.dovepress.com/the-abc7-regimen-a-new-approach-to-metastatic-breast-cancer-using-seve-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Richard E Kast,1 Nicolas Skuli,2 Samuel Cos,3 Georg Karpel-Massler,4 Yusuke Shiozawa,5 Ran Goshen,6 Marc-Eric Halatsch4 1IIAIGC Study Center, Burlington, VT, USA; 2INSERM, Centre de Recherches en Cancérologie de Toulouse – CRCT, UMR1037 Inserm/Université Toulouse III – Paul Sabatier, Toulouse, France; 3Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Valdecilla Research Institute (IDIVAL), Santander, Spain; 4Department of Neurosurgery, Ulm University Hospital, Ulm, Germany; 5Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA; 6Eliaso Consulting Ltd., Tel Aviv-Yafo, Israel Abstract: Breast cancer metastatic to bone has a poor prognosis despite recent advances in our understanding of the biology of both bone and breast cancer. This article presents a new approach, the ABC7 regimen (Adjuvant for Breast Cancer treatment using seven repurposed drugs), to metastatic breast cancer. ABC7 aims to defeat aspects of epithelial-to-mesenchymal transition (EMT) that lead to dissemination of breast cancer to bone. As add-on to current standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and the added EMT occurring as a response to current treatment modalities. Chemotherapy, radiation, and surgery provoke EMT in cancer generally and in breast cancer specifically. ABC7 uses standard doses of capecitabine as used in treating breast cancer today. In addition, ABC7 uses 1) an older psychiatric drug, quetiapine, to block RANK signaling; 2) pirfenidone, an anti-fibrosis drug to block TGF-beta signaling; 3) rifabutin, an antibiotic to block beta-catenin signaling; 4) metformin, a first-line antidiabetic drug to stimulate AMPK and inhibit mammalian target of rapamycin, (mTOR); 5) propranolol, a beta-blocker to block beta-adrenergic signaling; 6) agomelatine, a melatonergic antidepressant to stimulate M1 and M2 melatonergic receptors; and 7) ribavirin, an antiviral drug to prevent eIF4E phosphorylation. All these block the signaling pathways – RANK, TGF-beta, mTOR, beta-adrenergic receptors, and phosphorylated eIF4E – that have been shown to trigger EMT and enhance breast cancer growth and so are worthwhile targets to inhibit. Agonism at MT1 and MT2 melatonergic receptors has been shown to inhibit both breast cancer EMT and growth. This ensemble was designed to be safe and augment capecitabine efficacy. Given the expected outcome of metastatic breast cancer as it stands today, ABC7 warrants a cautious trial. Keywords: ABC7, breast cancer, agomelatine, capecitabine, metformin, pirfenidone, propranolol, quetiapine, repurposing, ribavirin, rifabutin, TGF-betaKast RESkuli NCos SKarpel-Massler GShiozawa YGoshen RHalatsch MEDove Medical PressarticleABC7breast canceragomelatinecapecitabinemetforminpirfenidonepropranololquetiapinerepurposingribavirinrifabutinTGF-betaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 495-514 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
ABC7 breast cancer agomelatine capecitabine metformin pirfenidone propranolol quetiapine repurposing ribavirin rifabutin TGF-beta Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
ABC7 breast cancer agomelatine capecitabine metformin pirfenidone propranolol quetiapine repurposing ribavirin rifabutin TGF-beta Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kast RE Skuli N Cos S Karpel-Massler G Shiozawa Y Goshen R Halatsch ME The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| description |
Richard E Kast,1 Nicolas Skuli,2 Samuel Cos,3 Georg Karpel-Massler,4 Yusuke Shiozawa,5 Ran Goshen,6 Marc-Eric Halatsch4 1IIAIGC Study Center, Burlington, VT, USA; 2INSERM, Centre de Recherches en Cancérologie de Toulouse – CRCT, UMR1037 Inserm/Université Toulouse III – Paul Sabatier, Toulouse, France; 3Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Valdecilla Research Institute (IDIVAL), Santander, Spain; 4Department of Neurosurgery, Ulm University Hospital, Ulm, Germany; 5Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA; 6Eliaso Consulting Ltd., Tel Aviv-Yafo, Israel Abstract: Breast cancer metastatic to bone has a poor prognosis despite recent advances in our understanding of the biology of both bone and breast cancer. This article presents a new approach, the ABC7 regimen (Adjuvant for Breast Cancer treatment using seven repurposed drugs), to metastatic breast cancer. ABC7 aims to defeat aspects of epithelial-to-mesenchymal transition (EMT) that lead to dissemination of breast cancer to bone. As add-on to current standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and the added EMT occurring as a response to current treatment modalities. Chemotherapy, radiation, and surgery provoke EMT in cancer generally and in breast cancer specifically. ABC7 uses standard doses of capecitabine as used in treating breast cancer today. In addition, ABC7 uses 1) an older psychiatric drug, quetiapine, to block RANK signaling; 2) pirfenidone, an anti-fibrosis drug to block TGF-beta signaling; 3) rifabutin, an antibiotic to block beta-catenin signaling; 4) metformin, a first-line antidiabetic drug to stimulate AMPK and inhibit mammalian target of rapamycin, (mTOR); 5) propranolol, a beta-blocker to block beta-adrenergic signaling; 6) agomelatine, a melatonergic antidepressant to stimulate M1 and M2 melatonergic receptors; and 7) ribavirin, an antiviral drug to prevent eIF4E phosphorylation. All these block the signaling pathways – RANK, TGF-beta, mTOR, beta-adrenergic receptors, and phosphorylated eIF4E – that have been shown to trigger EMT and enhance breast cancer growth and so are worthwhile targets to inhibit. Agonism at MT1 and MT2 melatonergic receptors has been shown to inhibit both breast cancer EMT and growth. This ensemble was designed to be safe and augment capecitabine efficacy. Given the expected outcome of metastatic breast cancer as it stands today, ABC7 warrants a cautious trial. Keywords: ABC7, breast cancer, agomelatine, capecitabine, metformin, pirfenidone, propranolol, quetiapine, repurposing, ribavirin, rifabutin, TGF-beta |
| format |
article |
| author |
Kast RE Skuli N Cos S Karpel-Massler G Shiozawa Y Goshen R Halatsch ME |
| author_facet |
Kast RE Skuli N Cos S Karpel-Massler G Shiozawa Y Goshen R Halatsch ME |
| author_sort |
Kast RE |
| title |
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| title_short |
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| title_full |
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| title_fullStr |
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| title_full_unstemmed |
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| title_sort |
abc7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/4e6e679f64db42edab80fb791718a624 |
| work_keys_str_mv |
AT kastre theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT skulin theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT coss theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT karpelmasslerg theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT shiozaway theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT goshenr theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT halatschme theabc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT kastre abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT skulin abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT coss abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT karpelmasslerg abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT shiozaway abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT goshenr abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy AT halatschme abc7regimenanewapproachtometastaticbreastcancerusingsevencommondrugstoinhibitepithelialtomesenchymaltransitionandaugmentcapecitabineefficacy |
| _version_ |
1718401310164779008 |